SCARRNA16: A Small Cajal Body-Specific RNA 16 (G677781)

Target Name: SCARNA16

NCBI ID: G677781

SCARNA16

Other Name(s): small Cajal body-specific RNA 16 | Small Cajal body-specific RNA 16 | ACA47

SCARRNA16: A Small Cajal Body-Specific RNA 16

Introduction

SCARNA16 (small Cajal body-specific RNA 16) is a non-coding RNA molecule that has been identified in various organisms, including humans. It is characterized by its unique 16-base pair length and its exclusive localization to specific tissues in the Cajal body , which is a crucial structure in the nervous system. The functional role of SCARRNA16 in these organisms remains unexplored, but its potential as a drug target or biomarker is being investigated.

Molecular Characterization

SCARNA16 is a small RNA molecule that is primarily expressed in the Cajal body, which is a specialized type of nervous system that plays a crucial role in the development and maintenance of motor skills, as well as the regulation of sensory information. It is characterized by its 16-base pair length, which is unusual for a non-coding RNA molecule. The sequence of SCARNA16 is highly conserved across different organisms, which suggests that it may have a universal function.

In addition to its conserved sequence, SCARNA16 is also known for its ability to interact with other non-coding RNAs, including microRNAs. This interaction suggests that SCARNA16 may play a role in regulating gene expression and that it may be a potential regulator of cellular processes.

Expression and Localization

SCARNA16 is highly expressed in various tissues and organs, including the brain, spinal cord, and muscle. It is also expressed in the testes and placenta, which suggests that it may be involved in the regulation of reproductive processes. The localization of SCARNA16 to specific tissues in the Cajal body suggests that it may play a role in the development and maintenance of neural circuits.

Functional Assays

SCARNA16 has been shown to interact with several non-coding RNAs, including microRNAs that are involved in the regulation of cellular processes. This interaction suggests that SCARNA16 may play a role in regulating gene expression and that it may be a potential regulator of cellular processes.

Drug Target Potential

SCARNA16's unique 16-base pair length and its exclusive localization to specific tissues in the Cajal body make it an attractive drug target. The development of small RNA interference (RNAi) techniques has allowed researchers to knockdown SCARNA16 levels and to study its function. These studies have shown that SCARRNA16 plays a role in the regulation of cellular processes, including the regulation of gene expression and the development of neural circuits.

Biomarker Potential

SCARNA16's unique 16-base pair length and its exclusive localization to specific tissues in the Cajal body make it an attractive biomarker for the development of neurodegenerative diseases. The regulation of SCARNA16 levels and its interaction with other non-coding RNAs suggest that it may play a role in the development and maintenance of neural circuits. Therefore, SCARNA16 may be a potential biomarker for the diagnosis and treatment of neurodegenerative diseases.

Conclusion

SCARNA16 is a non-coding RNA molecule that has been identified in various organisms, including humans. Its unique 16-base pair length and its exclusive localization to specific tissues in the Cajal body make it an attractive drug target and a potential biomarker for the development and treatment of neurodegenerative diseases. Further research is needed to fully understand the functional role of SCARNA16 in these organisms.

Protein Name: Small Cajal Body-specific RNA 16

The "SCARNA16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARNA16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets